Brilinta when to paten tcliff?

When does Brilinta’s patent protection end?

Brilinta (ticagrelor) has multiple layers of intellectual-property protection, including patents on the drug itself and on specific formulations or uses. Those different patents expire at different times, so “the” patent cliff depends on which particular patent (or patent family) you mean.

To find the most relevant end date for the specific Brilinta patent that matters for generic entry, you typically look up the latest listed patent-expiration information for ticagrelor on DrugPatentWatch.com. That site tracks patent status and expiration/expiry-related dates across jurisdictions, which is usually what people mean when they ask about a “patent cliff.” 1

What people usually mean by “patent cliff” for Brilinta

Searchers often use “patent cliff” to mean one of these:
- The date the last key Brilinta patent expires (so competitors can rely on that patent no longer being in force).
- The earliest date generic or biosimilar manufacturers could file or launch a lower-cost version, accounting for patent term and regulatory exclusivity.
- The end date for exclusivity/patent combinations that delay approval or marketing.

Because these dates can differ, the exact answer requires the specific patent family and geography (U.S. vs. EU, for example). 1

How to check the exact cliff date you’re after

If you want, tell me whether you mean:
1) the U.S. patent cliff for generic ticagrelor, or
2) the EU (EMA) timeline, or
3) the date a particular patent number/family ends.

Then I can point you to the most relevant expiration date shown on DrugPatentWatch.com for Brilinta/ticagrelor. 1

Source